A Better Night’s Sleep Lemborexant’s Proven Dosing Strategy for Insomnia Relief

A leading Japanese pharmaceutical company has filed a patent covering specific dosing methods for lemborexant – a dual orexin receptor antagonist approved for treating insomnia – demonstrating how precise doses of 5 mg or 10 mg can measurably improve key sleep parameters including how quickly patients fall asleep, how efficiently they sleep and how much time they spend awake after first falling asleep. The patent protects a data-backed dosing regime that could inform clinical practice for millions of insomnia sufferers.

The Problem

Sleep disorders, particularly insomnia, are among the most common health complaints worldwide. The condition is characterised by difficulties with sleep onset, sleep maintenance or early morning awakening, along with daytime impairment that affects work, relationships and quality of life. Chronic insomnia affects an estimated 10 to 15 per cent of the adult population in developed countries, making it a major public health issue.

For decades, the primary pharmacological treatments for insomnia included benzodiazepines and non-benzodiazepine receptor agonists (such as zopiclone and zolpidem) – medications that work by broadly suppressing the central nervous system. While effective, these drugs carry significant risks including dependence, tolerance, next-day sedation and cognitive impairment. There has long been a recognised need for a safer, more targeted approach.

The orexin system – a network of neuropeptides that actively promotes wakefulness – has emerged as a more precise therapeutic target. By blocking the orexin receptors (OX1R and OX2R) that keep the brain’s wake-promoting systems active, orexin receptor antagonists can reduce wakefulness at night without the broad central nervous system suppression associated with older sleep medications. However, identifying the right dose to balance efficacy and tolerability has been critical to clinical success.

What This Invention Does

This patent covers methods of treating insomnia using lemborexant at specific doses – 5 mg or 10 mg – to achieve measurable improvements in three key subjective sleep outcomes. The first is subjective sleep efficiency (sSE), which measures the proportion of time in bed that a patient actually spends asleep. The second is subjective sleep onset latency (sSOL), the time it takes a patient to fall asleep after going to bed. The third is subjective wake after sleep onset (sWASO), the total time a patient spends awake after first falling asleep during the night.

The patent establishes that administration of 5 mg or 10 mg of lemborexant – or an equivalent dose of a pharmaceutically acceptable salt – demonstrably improves all three of these parameters. This is significant because it provides a clear, evidence-based dosing framework backed by clinical data, giving prescribers and regulators confidence in these specific doses rather than relying on general dose range guidance.

The method also covers lemborexant formulated as a pharmaceutically acceptable salt, extending protection to chemically equivalent forms of the active compound that may be used in different formulations.

Key Features

Specific effective dose identification. The patent identifies 5 mg and 10 mg as the specific doses of lemborexant that produce measurable improvements in subjective sleep outcomes – providing clinically actionable dosing guidance supported by evidence.

Three-parameter sleep improvement. The invention addresses sleep efficiency, sleep onset latency and wake after sleep onset together, reflecting a comprehensive approach to sleep quality improvement rather than targeting a single parameter.

Dual orexin receptor antagonism. Lemborexant works by blocking both orexin-1 and orexin-2 receptors – the molecules responsible for maintaining wakefulness – providing a targeted mechanism of action distinct from older sedative-hypnotic drugs.

Salt form coverage. The method extends to pharmaceutically acceptable salt forms of lemborexant, ensuring comprehensive intellectual property protection across the range of formulation options.

Patient-reported outcome focus. By focusing on subjective rather than only objective sleep measures, the patent reflects real-world patient experience – the quality of sleep as the patient perceives it – which is increasingly recognised as the most clinically meaningful endpoint in insomnia treatment.

Who Is Behind It?

Eisai R&D Management Co., Ltd. is the research and development subsidiary of Eisai Co., Ltd., a major Japanese pharmaceutical company. Eisai developed lemborexant under the brand name Dayvigo, which received approval from the US Food and Drug Administration in 2019 and the Australian Therapeutic Goods Administration subsequently. The inventors are Margaret Moline, Lynn Kramer and Shobha Dhadda. This Australian application is a divisional of AU 2020307991 and is managed by Davies Collison Cave Pty Ltd in Milton, Queensland.

Why It Matters

Insomnia is a condition where the right drug at the right dose can make a profound difference to a patient’s daily functioning and quality of life. Lemborexant represents a genuine advance over older sleep medications – its targeted orexin antagonism mechanism offers efficacy with a more favourable safety profile than benzodiazepines, including a lower risk of dependence and next-morning impairment.

The data-backed dosing claims in this patent are important not just commercially but clinically – they give prescribers a clear, evidence-supported framework for selecting between the 5 mg and 10 mg doses based on patient needs. With IPC classifications covering heterocyclic compound pharmacology (A61K 31/519) and combination drug therapies (A61K 45/06), the patent sits at the core of Eisai’s clinical investment in insomnia treatment and reflects the rigorous clinical development programme behind one of the field’s most carefully validated sleep medicines.

---

AU 2026201519 was published in the Australian Official Journal of Patents on 19 March 2026 and is open for public inspection. Patent applications represent inventions that are sought to be protected and do not necessarily reflect commercially available products.

Related Concepts

Insomnia affects an estimated 10–15% of adults in developed countries, making it a major public health burden. The orexin system – a group of wakefulness-promoting neuropeptides – has become a key pharmacological target, offering more selective sedation than older benzodiazepine drugs. Lemborexant (Dayvigo) is a dual orexin receptor antagonist approved in Australia, the US, Canada and Japan for treating adults with insomnia.